소화기 및 장내 치료제 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 연령별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Digestive & Intestinal Remedies Market Growth & Trends:

The global digestive & intestinal remedies market size is estimated to reach USD 27.54 billion by 2030, expanding at a CAGR of 4.25% from 2025 to 2030, according to a new report by Grand View Research, Inc. Digestive medicines are the most common over the counter medicines purchased by people. Moreover, physicians recommend the use of these medicines only after minor health issues such as acidity and other digestive problems. But in several countries, these medicines are sold directly to the patients without prescription as per their rules and regulations.

The market is majorly driven by high demand for over-the-counter products such as zientac, omez, and others. There is an increase in gastrointestinal disorders cases among people. Moreover, increasing cases of inflammatory bowel disease, constipation, irritable bowel syndrome, and gastroesophageal reflux illness are other factors that in turn are boosting market growth over the forecast period.

The market growth is driven by the developments and expansion of fast-food joints and the food service industry. Due to the expansion of hotels, restaurants, and junk food places across the world, consumption of oily, spicy, and unhygienic food has increased extremely. Moreover, increasing disposable income and a hectic lifestyle are facilitating the trend of eating out. This significantly leads to digestive and intestinal problems such as acidity, upset stomach, inflammations, etc., and increases consumption of digestive and intestinal remedies.

During the COVID-19 pandemic, the sales of digestive and intestinal remedies were reduced globally. Lockdown measures to control the spread of COVID-19 and better hygiene have frozen the spread of seasonal illnesses, which has reduced the sales of over-the-counter medicines. Various pharmaceutical companies have displayed quarterly earnings reports which showed that a decrease in digestive and intestinal remedies has affected their bottom line sales in the market.

The digestive medicines accounted for the largest revenue share of over 50% in 2021 owing to the increasing demand for these drugs due to rising health issues. The rising aging population is also another key factor driving the segment growth. Moreover, altering lifestyles and diets has also increased the demand for digestive remedies products. Hence, owing to these reasons the segment is estimated to show growth over the estimated period.

The offline segment dominated the market with the highest share of over 70% in 2021. The demand for digestives & intestinal remedies is rising among customers due to more sustainability offered by these offline stores than any other channel. Hence the segment is projected to show growth during the assessment period.

North America dominated the market and accounted for around 45% revenue share in 2021 due to the growing number of gastrointestinal diseases in this region. Also, the growing geriatric and obese population in this region is driving the market growth. Increasing research and development activities along with the presence of key market players are other factors boosting market growth over the forecast period.

Digestive & Intestinal Remedies Market Report Highlights:

• Asia Pacific digestive & intestinal remedies market is expected to experience the fastest growth globally owing to rising demand for digestives & intestinal remedies due to the increasing prevalence of GI illness disease
• The digestive medicines accounted for the largest revenue share of over 51.98% in 2024 owing to the increasing demand for these drugs due to rising health issues
• The offline segment dominated the market with the highest share of 4.11% in 2024 owing to its increasing sales
• The remedies against gastrointestinal complaints segment is expected to register significant market growth during the forecast period owing to growing research and development in remedies against gastrointestinal complaints.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Age group
  • 1.2.3. Distribution channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product and age group outlook
  • 2.2.2. Distribution channel outlook
• 2.3. Competitive Insights

Chapter 3. Digestive & Intestinal Remedies Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising incidence of digestive disorders
    • 3.2.1.2. Rising awareness about disease
    • 3.2.1.3. Technological advancement
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Stringent regulations pertaining to drug approval
    • 3.2.2.2. Market saturation and high competition
• 3.3. Digestive & Intestinal Remedies Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Digestive & Intestinal Remedies Market: Type Estimates & Trend Analysis

• 4.1. Global Digestive & Intestinal Remedies Market: Type Segment Dashboard
• 4.2. Global Digestive & Intestinal Remedies Market: Type Movement Analysis
• 4.3. Global Digestive & Intestinal Remedies Market Estimates and Forecasts, By Type, Revenue (USD Million)
• 4.4. Digestive Medicines
  • 4.4.1. Digestive medicines market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Remedies Against Gastrointestinal Complaints
  • 4.5.1. Remedies against gastrointestinal complaints market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Natural and Synthetic Agents
  • 4.6.1. Natural and synthetic agents market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Digestive & Intestinal Remedies Market: Age Group Estimates & Trend Analysis

• 5.1. Global Digestive & Intestinal Remedies Market: Age Group Segment Dashboard
• 5.2. Global Digestive & Intestinal Remedies Market: Age Group Movement Analysis
• 5.3. Global Digestive & Intestinal Remedies Market Estimates and Forecasts, By Age Group, Revenue (USD Million)
• 5.4. Adult & Geriatric
  • 5.4.1. Adult & geriatric market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Pediatric
  • 5.5.1. Pediatric market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Digestive & Intestinal Remedies Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Global Digestive & Intestinal Remedies Market: Distribution Channel Segment Dashboard
• 6.2. Global Digestive & Intestinal Remedies Market: Distribution Channel Movement Analysis
• 6.3. Global Digestive & Intestinal Remedies Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
• 6.4. Offline
  • 6.4.1. Offline market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Online
  • 6.5.1. Online market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Digestive & Intestinal Remedies Market: Regional Estimates & Trend Analysis By Product, Application, and End Use

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company market share analysis, 2024
  • 8.3.2. Bayer AG
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Product benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Johnson & Johnson Services Inc.
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Product benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. GSK plc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Procter & Gamble
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Sanofi
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Boehringer Ingelheim GmbH
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Reckitt Benckiser Group PLC
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Abbott
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Takeda Pharmaceutical Company Limited
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Menarini Group
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives